文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-PSMA PET/CT 对前列腺癌放疗方案的影响:与 CT 的回顾性对比分析

Impact of 68Ga-PSMA PET/CT on the Radiotherapeutic Approach to Prostate Cancer in Comparison to CT: A Retrospective Analysis.
PubMed 文献 · J Nucl Med · 2018-12-14

该回顾性分析纳入 172 例放疗前接受 68Ga-PSMA PET/CT 的前列腺癌患者,比较 PET/CT 与 CT 对放疗决策的影响。PET/CT 总体检出率 70%,联合 PET/CT 信息后 107/172(62%)患者治疗方案发生改变,术后 PSA 持续或复发患者改变率更高。

要点

  • 68Ga-PSMA PET/CT 总体检出率为 70%(120/172)。
  • PET/CT 使 62%(107/172)患者放疗方案发生改变。
  • 术后 PSA 持续患者方案改变率最高,达 77%(68/88)。

核心结论

  • 与常规 CT 相比,68Ga-PSMA PET/CT 对前列腺癌放疗方案有显著影响,尤其在术后患者中。

研究设计与样本

  • 回顾性分析纳入 2014 年 2 月至 2017 年 12 月放疗前接受 68Ga-PSMA PET/CT 的 172 例前列腺癌患者。
  • 22 例(13%)为根治性放疗前,88 例(51%)为根治性前列腺切除术后 PSA 持续,62 例(36%)为术后 PSA 复发。
  • 由对 CT 和 PET/CT 结果设盲的放疗肿瘤学家根据临床和病理变量决定放疗管理。

主要发现

  • 68Ga-PSMA PET/CT 总体检出率为 70%(120/172)。
  • PET/CT 前 PSA 水平大于 0.5 ng/mL 的患者 PET 阳性结果显著更多(98/111;88%)。
  • PSMA PET/CT 共显示 171 个病灶,单独 PET 显示 156 个,单独 CT 显示 85 个。
  • CT 与 PET/CT 对比:原发肿瘤/局部复发阳性发现分别为 18% 与 37%,盆腔淋巴结为 21% 与 44%,远处转移为 7% 与 19%。
  • 联合 PET/CT 信息后,107/172(62%)患者治疗发生改变:未治疗前 8/22(36%),PSA 复发 31/62(50%),PSA 持续 68/88(77%)。

关键数值与推荐

  • PET/CT 前 PSA 水平大于 0.5 ng/mL 与 PET 阳性结果显著更多相关(98/111;88%)。
  • 术后患者的管理改变率高于未治疗前患者。

临床怎么用

  • 对于放疗前前列腺癌患者,尤其是根治性前列腺切除术后 PSA 持续或复发者,68Ga-PSMA PET/CT 可提供比 CT 更准确的分期信息并影响放疗决策。
  • 德国 S3 指南和欧洲泌尿外科学会指南已认可 68Ga-PSMA PET/CT 用于 PSA 持续或复发患者的影像学检查。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

68Ga-prostate-specific membrane antigen PET/CT (68Ga-PSMA PET/CT) offers unprecedented accuracy for staging of primary, persistent, or recurrent prostate cancer. Thus, we hypothesized that 68Ga-PSMA PET/CT before radiotherapy significantly affects the radiotherapeutic approach in comparison to the current standard, a CT-based approach. Methods: Between February 2014 and December 2017, 172 patients underwent 68Ga-PSMA PET/CT before radiotherapy and were included in this retrospective analysis. Twenty-two (13%) patients were referred for primary definitive radiotherapy, 51% (88/172) for prostate-specific antigen (PSA) persistence, and 36% (62/172) for PSA recurrence after radical prostatectomy. An experienced radiation oncologist, masked to the CT and PET/CT results, decided on the radiation treatment management of all patients on the basis of the clinical and pathologic variables. The potential increase in diagnostic accuracy, and the subsequent change in radiotherapeutic approach, were documented separately for PET/CT versus CT. Results: The overall detection rate was 70% (120/172) for 68Ga-PSMA PET/CT. Patients with a pre-PET/CT PSA level of more than 0.5 ng/mL (98/111; 88%) had PET-positive results significantly more often. Overall, PSMA PET/CT revealed 171 lesions, PET alone 156, and CT alone 85. For all patients, a continuous diagnostic increase in positive findings was observed for primary tumor/local recurrence (CT, 18%, vs. PET/CT, 37%), pelvic lymph nodes (CT, 21%, vs. PET/CT, 44%), and distant metastases (CT, 7%, vs. PET/CT, 19%) when comparing CT with PET/CT. Compared with CT, the combination of PET/CT information resulted in a change in treatment in 107 of 172 (62%) patients, that is, 8 of 22 (36%) patients before any treatment, 31 of 62 (50%) with PSA recurrence, and 68 of 88 (77%) with PSA persistence. Comparing the different radiotherapy indications with one another, there was a higher rate of change in management for postoperative patients than for patients before any treatment. Conclusion: Compared with conventional CT, 68Ga-PSMA PET/CT had a remarkable impact on radiotherapeutic approach, especially in postoperative patients. Thus, considering the growing amount of data on the impact of 68Ga-PSMA PET/CT on postoperative patients, 68Ga-PSMA PET/CT has recently been endorsed by a few cancer guidelines as an imaging modality in patients with PSA persistence or recurrence (e.g., the German S3 guideline and the European Association of Urology guideline).

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Schmidt-Hegemann NS, Eze C, Li M, et al. Impact of 68Ga-PSMA PET/CT on the Radiotherapeutic Approach to Prostate Cancer in Comparison to CT: A Retrospective Analysis. J Nucl Med. 2018. PMID: 30552203. doi:10.2967/jnumed.118.220855

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。